Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons
A Gisina, Y Kim, K Yarygin, A Lupatov - International Journal of Molecular …, 2023 - mdpi.com
The CD133 cell membrane glycoprotein, also termed prominin-1, is expressed on some of
the tumor cells of both solid and blood malignancies. The CD133-positive tumor cells were …
the tumor cells of both solid and blood malignancies. The CD133-positive tumor cells were …
The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection
A Gisina, K Yarygin, A Lupatov - Biology, 2024 - mdpi.com
The membrane glycoprotein CD133 (prominin-1) is widely regarded as the main molecular
marker of cancer stem cells, which are the most malignant cell subpopulation within the …
marker of cancer stem cells, which are the most malignant cell subpopulation within the …
[HTML][HTML] The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells
M Kucinska, J Pospieszna, J Tang, N Lisiak… - Biomedicine & …, 2024 - Elsevier
The lesson from many studies investigating the efficacy of targeted therapy in glioblastoma
(GBM) showed that a future perspective should be focused on combining multiple target …
(GBM) showed that a future perspective should be focused on combining multiple target …
[HTML][HTML] CD133, CD47, and PD-L1 Expression in Ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study
Results: Strong expression of CD133 and CD47 was seen in 52% and 66% of tissue
samples, respectively. Twenty of the thirty-one patients with metastases had a significant …
samples, respectively. Twenty of the thirty-one patients with metastases had a significant …
Expression of stem cell markers as predictors of therapeutic response in metastatic prostate cancer patients
S Nandagopal, G Choudhary, S Sankanagoudar… - … Oncology: Seminars and …, 2024 - Elsevier
Abstract Background Cancer stem cells (CSCs) have been implicated in prostate cancer
(PCA) progression and therapeutic resistance. This study aimed to compare the expression …
(PCA) progression and therapeutic resistance. This study aimed to compare the expression …
Histopathological and Molecular Markers in the Assessment of Prostate Cancer Aggressivity
LJ Velickovic - Prostate Cancer: Advancements in the Pathogenesis …, 2024 - Springer
Prostate cancer (PCa) in most patients does not cause significant clinical symptoms, but
high-risk disease, accounting for approximately 15% of PCa, has the potential to progress to …
high-risk disease, accounting for approximately 15% of PCa, has the potential to progress to …